To account for this prediction, we first investigated the cellular effects of Spiclomazine on activated KRasG12C (MIA PaCa-2), KRasG12V (CFPAC-1), and wild-type KRas (BxPC-3) pancreatic cancer cell lines by monitoring the active KRas-GTP level. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.